clopidogrel
The new reports link variants in CYP2C19 to the safety and efficacy of two drugs, a commonly prescribed antiplatelet drug and an antidepressant.
Meta-Analysis Supports Pharmacogenomic Testing Prior to Anti-Platelet Therapy
The study showed that CYP2C19 genotyping could help clinicians reduce ischemic events in patients with coronary artery disease by tailoring their treatment.
The community is poised to be the primary channel for stakeholders to communicate PGx concerns with FDA, but it is unclear if all stakeholders will participate.
Trial Shows Some Benefit of Genetically Guided Antiplatelet Therapy After Balloon Angioplasty
The TAILOR-PCI trial did not meet its primary endpoint but did find that genetic testing led to a reduction in adverse events, though not as much as expected.
23andMe Garners FDA Clearance for CYP2C19 PGx Test Report
The firm can now tell customers if their genotypes may impact their response to clopidogrel and citalopram without the need for confirmatory testing.